Zu den Inhalten springen

Klinik für Innere Medizin IHämatologie, Onkologie und Stammzelltransplantation

Leitender Oberarzt

Prof. Dr. med. Jürgen Finke
Prof. Dr. med. Jürgen Finke

juergen.finke@uniklinik-freiburg.de

Sekretariat Frau P. Steuer
Telefon +49 (0) 761 270-33640
Telefax +49 (0) 761 270-36580
E-Mail: petra.steuer@uniklinik-freiburg.de

Nach Abschluss des Medizinstudiums an der Albert-Ludwigs Universität Freiburg 1983 berufliche Tätigkeiten an der Medizinischen Universitätsklinik Göttingen, am Department of Tumorbiology, Karolinska Institut, Stockholm, Schweden bei Prof. G. Klein und seit 1987 an der Medizinischen Universitätsklinik Freiburg. Seit 1993 Oberarzt an der Medizinischen Universitätsklinik Freiburg, Abteilung Hämatologie/ Onkologie und seit 1994 verantwortlicher Leiter des allogenen Stammzelltransplantationsprogrammes. Seit 2000 außerplanmäßiger Professor der medizinischen Fakultät der Albert-Ludwigs-Universität Freiburg, seit 2002 leitender Oberarzt der Abteilung Innere Medizin I und Leiter der Sektion "allogene Stammzelltransplantation" und seit 2009 Sprecher der Deutschen Arbeitsgemeinschaft Knochenmark- und Blutstammzelltransplantation (DAG-KBT).

Schwerpunkte der klinischen Forschung sind die Weiterentwicklung der allogenen Transplantationsverfahren, insbesondere der Fremdspendertransplantation und der peripheren Blutstammzelltransplantation, auch für ältere Patienten, sowie Patienten mit soliden Tumoren und malignen Lymphomen und die Verbesserung der allogenen Immuntherapie.Schwerpunkte der klinischen und Labor-basierenden Forschung sind die Therapie maligner Lymphome, insbesondere des Zentralnervensystems, sowie die Therapie von Autoimmunkrankheiten mit Hochdosistherapie und autologer Stammzelltransplantation.

Curriculum vitae

After studying medicine Freiburg University Medical School, Germany and University of Glasgow Medical School J. Finke graduated 1983 in Freiburg. After working at the Department of Medicine, Göttingen University Hospital, Germany and at the Department of Tumorbiology in the group of Professor George Klein at the Karolinska Institute, Stockholm, Sweden, he joined the Department of Medicine, Freiburg University Hospital in 1987. Since 1993 J. Finke is consultant at the Dept. Hematology and Oncology, since 2002 as deputy head at the department. He is head of the section allogeneic stem cell transplantation and since 2009 chairman of the German stem cell transplant working group (DAG-KBT).

  1. Metaxas,Y., Zeiser,R., Schmitt-Graeff,A., Waterhouse,M., Faber,P., Follo,M., Bertz,H., Finke,J., and Spyridonidis,A. Human hematopoietic cell transplantation results in generation of donor-derived epithelial cells. Leukemia 19, 1287-1289.(2005).
  2. Reinhardt,M.J., Herkel,C., Altehoefer,C., Finke,J., and Moser,E. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Ann. Oncol. 16, 1524-1529.(2005).
  3. Spyridonidis,A., Kuttler,T., Wasch,R., Samek,E., Waterhouse,M., Behringer,D., Bertz,H., and Finke,J. Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin. Stem Cells Dev. 14, 213-222.(2005).
  4. Spyridonidis,A., Bertz,H., Ihorst,G., Grullich,C., and Finke,J. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (>= 60 years) with active myeloid malignancies. Blood 105, 4147-4148.(2005).
  5. Spyridonidis,A., Zeiser,R., Wasch,R., Bertz,H., and Finke,J. Capillary electrophoresis for chimerism monitoring by PCR amplification of microsatellite markers after allogeneic hematopoietic cell transplantation. Clin. Transplant. 19, 350-356.(2005).
  6. Zeiser,R., Spyridonidis,A., Wasch,R., Ihorst,G., Grullich,C., Bertz,H., and Finke,J. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia 19, 814-821.(2005).
  7. Faber,P., Fisch,P., Waterhouse,M., Schmitt-Graff,A., Bertz,H., Finke,J., and Spyridonidis,A. Frequent genomic alterations in epithelium measured by microsatellite instability following allogeneic hematopoietic cell transplantation in humans. Blood 107, 3389-3396.(2006).
  8. Illerhaus,G., Marks,R., Ihorst,G., Guttenberger,R., Ostertag,C., Derigs,G., Frickhofen,N., Feuerhake,F., Volk,B., and Finke,J. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J. Clin. Oncol. 24, 3865-3870.(2006).
  9. Zeiser,R. and Finke,J. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect. Eur. J Cancer 42, 1601-1611.(2006).
  10. Auw-Haedrich,C., Potsch,C., Bohringer,D., Mittelviefhaus,H., Maier,P., Reinhard,T., Freudenberg,N.,Finke,J., and Coupland,S.E. Histological and immunohistochemical characterisation of conjunctival graft vs host disease following haematopoietic stem cell transplantation. Graefes Arch. Clin. Exp. Ophthalmol. 245, 1001-1007.(2007).
  11. Finke,J. and Nagler,A. Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia. Leukemia 21, 1357-1362.(2007).
  12. Heining,C., Spyridonidis,A., Bernhardt,E., Schulte-Monting,J., Behringer,D., Grullich,C., Jakob,A., Bertz,H., and Finke,J. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. Bone Marrow Transplant. 39, 613-622.(2007).
  13. Metaxas,Y., Spyridonidis,A., Bertz,H., Finke,J., and Greiner,J. Donor-derived mucosal epithelial cells after human hematopoietic cell transplantation are not derived from the CD34-positive fraction of the graft. Leukemia 21, 2214-2216.(2007).
  14. Schmid,C., Labopin,M., Nagler,A., Bornhauser,M., Finke,J., Fassas,A., Volin,L., Gurman,G., Maertens,J., Bordigoni,P., Holler,E., Ehninger,G., Polge,E., Gorin,N.C., Kolb,H.J., and Rocha,V. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin. Oncol. 25, 4938-4945.(2007).
  15. Thomas-Kaskel,A.K., Portugal,T.G., Herchenbach,D., Houet,L., Veelken,H., and Finke,J. Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes. Acta Haematol. 117, 226-235.(2007).
  16. Veelken,H., Vik,D.S., Schulte,M.J., Martens,U.M., Finke,J., and Schmitt-Graeff,A. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann. Oncol. 18, 931-939.(2007).
  17. Grullich,C., Friske,V., and Finke,J. Ex vivo detection of primary leukemia cells resistant to granule cytotoxin-induced cell death: a rapid isolation method to study granzyme-B-mediated cell death. Ann. Hematol. 87, 701-708.(2008).
  18. Grullich,C., Bertz,H., Spyridonidis,A., Muller,C.I., and Finke,J. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. Bone Marrow Transplant. 41, 845-850.(2008).
  19. Illerhaus,G., Muller,F., Feuerhake,F., Schafer,A.O., Ostertag,C., and Finke,J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93, 147-148.(2008).
  20. Marks,R., Potthoff,K., Hahn,J., Ihorst,G., Bertz,H., Spyridonidis,A., Holler,E., and Finke,J.M. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 112, 415-425.(2008).
  21. Spyridonidis,A., Bertz,H., Waterhouse,M., and Finke,J. Long-term lymphoid-restricted split chimerism after myeloablative allogeneic BMT for bcr-abl+ ALL. Bone Marrow Transplant. 42, 829-831.(2008).
  22. Zander,A.R., Bacher,U., and Finke,J. Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification. Dtsch. Arztebl. Int. 105, 663-669.(2008).
  23. Avivi,I., Montoto,S., Canals,C., Maertens,J., Al-Ali,H., Mufti,G.J., Finke,J., Schattenberg,A., Fanin,R., Cornelissen,J.J., Vernant,J.P., Russell,N., Beguin,Y., Thomson,K., Verdonck,L.F., Kobbe,G., Tilly,H., Socie,G., and Sureda,A. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br. J. Haematol. 147, 719-728.(2009).
  24. Bertz,H., Spyridonidis,A., Wasch,R., Grullich,C., Egger,M., and Finke,J. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol. Blood Marrow Transplant. 15, 1563-1570.(2009).
  25. Dilger,K., Halter,J., Bertz,H., Lopez-Lazaro,L., Gratwohl,A., and Finke,J. Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 15, 336-343.(2009).
  26. Eberwein,P., Faber,P., Reinhard,T., Finke,J., and Spyridonidis,A. Conjunctival epithelial cells with donor-derived genome after human haematopoietic stem-cell transplantation. Transplantation 87, 915-918.(2009).
  27. Finke,J., Bethge,W.A., Schmoor,C., Ottinger,H.D., Stelljes,M., Zander,A.R., Volin,L., Ruutu,T., Heim,D.A., Schwerdtfeger,R., Kolbe,K., Mayer,J., Maertens,J.A., Linkesch,W., Holler,E., Koza,V., Bornhauser,M., Einsele,H., Kolb,H.J., Bertz,H., Egger,M., Grishina,O., and Socie,G. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 10, 855-864.(2009).
  28. Grullich,C., Ziegler,C., and Finke,J. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. Biol. Blood Marrow Transplant. 15, 173-182.(2009).
  29. Illerhaus,G., Marks,R., Muller,F., Ihorst,G., Feuerhake,F., Deckert,M., Ostertag,C., and Finke,J. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann. Oncol. 20, 319-325.(2009).
  30. Lübbert,M., Bertz,H., Ruter,B., Marks,R., Claus,R., Wasch,R., and Finke,J. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 44, 585-588.(2009).
  31. Lübbert,M., Bertz,H., Wasch,R., Marks,R., Ruter,B., Claus,R., and Finke,J. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant.(2009).
  32. Ringden,O., Labopin,M., Ehninger,G., Niederwieser,D., Olsson,R., Basara,N., Finke,J., Schwerdtfeger,R., Eder,M., Bunjes,D., Gorin,N.C., Mohty,M., and Rocha,V. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J. Clin. Oncol. 27, 4570-4577.(2009).
  33. Schnitzler,M., Hasskarl,J., Egger,M., Bertz,H., and Finke,J. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol. Blood Marrow Transplant. 15, 910-918.(2009).
  34. Waterhouse,M., Themeli,M., Metaxas,Y., Lagadinou,E.D., Finke,J., and Spyridonidis,A. Horizontal DNA and mRNA transfer between donor and recipient cells after allogeneic hematopoietic cell transplantation? Front Biosci. 14, 2704-2713.(2009).
  35. Zeiser,R., Zerweck,A., Bertz,H., and Finke,J. Allogeneic hematopoietic cell transplantation for t-AML following liver transplantation from the same haploidentical donor. Bone Marrow Transplant. 43, 589-590.(2009)

Buchkapitel

  1. Finke, J. and Mertelsmann, R. (2008). Recombinant Growth Factors after Hematopoietic Cell Transplantation. In Thomas´ Hematopoietic Cell Transplantation, F.R. Appelbaum, S.J. Forman, R.S. Negrin, and K.G. Blume, eds. Wiley-Blackwell), pp. 645-656.
  2. Finke, J. (2009). Hodgkin´s disease and non-Hodgkin´s lymphoma. In Hematopoietic Stem Cell Transplantation, J. Treleaven and A.J. Barrett, eds. (Edinburgh: Churchill Livingstone Elsevier), pp. 97-104

Klinik für Innere Medizin I

Klinik für Tumorbiologie

Hämatologie, Onkologie und
Stammzelltransplantation

Hugstetter Straße 55
79106 Freiburg

Zentrale telefonische Anmeldung und Auskunft für alle Ambulanzen:

Frau A. Hahn
Telefon +49 (0) 761 270-35555
Telefax +49 (0) 761 270-78020
angelika.hahn@uniklinik-freiburg.de

Privatambulanz

Frau B. Hartmann
Telefon+49 (0) 761 270-34050
Telefax +49 (0) 761 270-32060
barbara.hartmann@uniklinik-freiburg.de